Clinical Trial Update: Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the combination of binimetinib and belinostat for metastatic uveal melanoma. The study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uveal Melanoma

Drugs mentioned

• Belinostat (belinostat)
• Binimetinib (binimetinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Metastatic Uveal Melanoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING